Flush with AZ cash, Almirall seeks dermatology assets
This article was originally published in Scrip
Almirall has fresh funds and wants to spend them on acquiring new dermatology assets, CEO Eduardo Sanchiz said following the surprise announcement that the Spanish firm is to sell its respiratory portfolio to AstraZeneca.
You may also be interested in...
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.